NASDAQ:INGN - Inogen Stock Price, Forecast & News

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Inogen Inc (NASDAQ:INGN) posted its quarterly earnings results on Tuesday, November, 5th. The medical technology company reported $0.31 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.23 by $0.08. The medical technology company earned $91.76 million during the quarter, compared to the consensus estimate of $91.65 million. Inogen had a net margin of 8.76% and a return on equity of 9.89%. The company's quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.73 earnings per share. View Inogen's Earnings History.

Inogen is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Inogen.

Inogen issued an update on its FY 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $361.4-362.4 million, compared to the consensus revenue estimate of $372.96 million.

7 brokers have issued 12 month price objectives for Inogen's stock. Their forecasts range from $47.00 to $90.00. On average, they anticipate Inogen's stock price to reach $65.00 in the next year. This suggests a possible upside of 31.5% from the stock's current price. View Analyst Price Targets for Inogen.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Inogen.

Media coverage about INGN stock has been trending extremely negative recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Inogen earned a news sentiment score of -5.0 on InfoTrie's scale. They also gave media headlines about the medical technology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Inogen.

Inogen saw a decline in short interest in December. As of December 13th, there was short interest totalling 2,340,000 shares, a decline of 6.8% from the November 28th total of 2,510,000 shares. Based on an average daily trading volume, of 342,300 shares, the short-interest ratio is presently 6.8 days. Currently, 12.9% of the shares of the stock are sold short. View Inogen's Current Options Chain.

Some companies that are related to Inogen include Wright Medical Group (WMGI), Wound Management Technologies (WNDM), Avanos Medical (AVNS), Establishment Labs (ESTA), Sientra (SIEN), RTI Surgical (RTIX), Invacare (IVC), Lakeland Industries (LAKE), ConforMIS (CFMS), Histogenics (HSGX), COLLPLANT HOLDI/S (CLGN), Rewalk Robotics (RWLK), NanoVibronix (NAOV), Precision Therapeutics (POAI) and Ocugen (OCGN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Medivation (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), First Solar (FSLR), Netflix (NFLX), Micron Technology (MU) and Celgene (CELG).

Inogen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Riverbridge Partners LLC (1.23%), Summit Creek Advisors LLC (0.66%), Chicago Capital LLC (0.12%), State of Alaska Department of Revenue (0.06%), Curbstone Financial Management Corp (0.05%) and Louisiana State Employees Retirement System (0.03%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Heather D Rider, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Institutional Ownership Trends for Inogen.

INGN stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Summit Creek Advisors LLC, Chicago Capital LLC, Curbstone Financial Management Corp, Louisiana State Employees Retirement System and State of Alaska Department of Revenue. View Insider Buying and Selling for Inogen.

Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of INGN stock can currently be purchased for approximately $49.43.

Inogen has a market capitalization of $1.09 billion and generates $358.11 million in revenue each year. The medical technology company earns $51.85 million in net income (profit) each year or $2.30 on an earnings per share basis. Inogen employs 1,099 workers across the globe.View Additional Information About Inogen.

The official website for Inogen is http://www.inogen.com/.

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]